Every 10-Q that Myomo Inc. (MYO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MYO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYO filings page.
Myomo, Inc. reported higher revenue and improved margins for the quarter ended June 30, 2026. Revenue grew to $11.7 million from $9.7 million a year earlier, and six‑month revenue rose to $21.8 million from $19.5 million. Gross margin expanded to 72.1% from 62.7% as higher average selling prices and manufacturing efficiencies outweighed increased clinical costs.
Operating expenses were essentially flat at $10.7 million for the quarter, with lower research and development spending and slightly higher general and administrative costs. Operating loss narrowed to $2.3 million from $4.6 million, and net loss improved to $4.0 million, or $0.09 per share, from $4.6 million, or $0.11 per share. For the first half, net loss was $7.0 million versus $8.1 million, while Adjusted EBITDA loss improved to $3.1 million from $6.8 million.
Cash, cash equivalents and short‑term investments totaled $13.5 million at June 30, 2026, with working capital of $13.9 million and operating cash use reduced to $4.1 million in the first half from $11.5 million a year earlier. A $17.5 million term‑loan facility with Avenue adds committed capital but increases interest expense and introduces derivative‑related fair value volatility, and carries covenants on minimum cash, revenue and cash burn. Revenue is driven mainly by direct billing to patients, U.S. and international O&P channels and the MyoConnect referral program, and remains highly dependent on Medicare and other insurance reimbursement, including updated CMS fee schedules for MyoPro devices.
Myomo, Inc. reported Q1 2026 revenue of $10.1 million, up about 3% from a year earlier, as higher average selling prices and international sales offset softer direct-to-patient volume. Gross margin improved to 68.2% from 67.2%, helped by pricing and lower material costs despite higher clinical expenses.
The company recorded a net loss of $3.0 million, narrowed from $3.5 million, and negative operating cash flow of $2.2 million. Adjusted EBITDA loss improved to $2.3 million from $2.8 million as operating expenses were roughly flat, with lower R&D and G&A partly offset by higher selling, clinical and marketing costs tied to advertising and new clinical sales staff.
Myomo ended the quarter with $15.7 million in cash, cash equivalents and short-term investments and working capital of $16.3 million. Long-term debt totaled $12.6 million under a Avenue term loan facility, whose derivative and warrant features produced a non-cash gain from a lower fair value. Management expects current liquidity to fund operations for at least 12 months while focusing on growing recurring MyoConnect and O&P channel revenues and reducing advertising-driven customer acquisition costs.
Myomo, Inc. reported Q3 2025 results with revenue of $10.09 million, up from $9.21 million a year ago. Gross margin declined to 63.8% from 75.4% as higher material costs, increased manufacturing overhead tied to the new headquarters, and less capitalized overhead weighed on profitability. The quarter’s operating loss was $3.52 million, and net loss was $3.66 million (basic and diluted loss per share $0.09).
For the nine months, revenue reached $29.57 million versus $20.48 million last year, while net loss was $11.76 million. Cash and cash equivalents were $12.55 million at September 30, 2025. Operating cash outflow was $13.37 million year‑to‑date. On the balance sheet, the company had $1.0 million outstanding on its revolving credit line and $3.0 million under its term loan facility.
After quarter‑end, Myomo entered a new loan agreement providing up to $17.5 million in committed capital, with $12.5 million funded on November 4, 2025. Management states current cash and expected cash flows are sufficient to fund operations for at least the next twelve months. Shares outstanding were 38,435,524 as of November 3, 2025.
Myomo, Inc. (MYO) reported strong top-line growth for the period ended June 30, 2025 with revenue of $9.65 million in the quarter, up 28% year-over-year, and $19.48 million for the six months, up 73% versus prior year. Higher sales were driven by more units and higher average selling prices following CMS reimbursement updates. Gross profit rose in absolute terms but gross margin narrowed to 62.7% in Q2 from 70.8% a year ago due to higher material and manufacturing overhead costs tied to a new headquarters and facility.
The company reported a quarterly net loss of $4.63 million (loss per share $0.11) and a six-month net loss of $8.10 million as operating expenses increased substantially: R&D +99% and selling, clinical & marketing +88% for the quarter. Cash, cash equivalents and short-term investments totaled about $15.48 million at June 30, 2025, and management states this funding is expected to cover operations for at least 12 months. The company drew $2.5 million on its revolving line and $1.5 million on its term loan during the quarter and disclosed a material weakness in IT general controls that is being remediated.